CoChat

Final efficacy analysis, interim safety analysis, and immunogenicity of a single dose of recombinant novel coronavirus vaccine (adenovirus type 5 vector) in adults 18 years and older: an international, multicentre, randomised, double-blinded, placebo-controlled phase 3 trial

Open access
Halperin, Scott A, Ye, Lingyun, MacKinnon-Cameron, Donna, Smith, Bruce, Cahn, Pedro E, Ruiz-Palacios, Guillermo M, Ikram, Aamer, Lanas, Fernando, Lourdes Guerrero, M, Muñoz Navarro, Sergio Raúl, Sued, Omar, Lioznov, Dmitry A, Dzutseva, Vitalina, Parveen, Ghazala, Zhu, Fengcai, Leppan, Laura, Langley, Joanne M, Barreto, Luis, Gou, Jinbo, Zhu, Tao, Mao, Helen, Gagnon, Luc, Tran, Steven-Phay, Khan, Sarwat Tahsin, Becerra Aquino, Amalia Guadalupe, Saldaña Montemayor, Edgar Eduardo, Rivera Martínez, Norma Eréndira, Bohórquez López, Víctor Casildo, Simón Campos, J. Abraham, Pineda Cárdenas, Felipe de Jesús, Chen, Wei, Hou, Lihua, Zhang, Zhe, Corral, Gonzalo, López, Eduardo, Teijeiro, Ricardo, Alzogaray, Maria F., Zaidman, Cesar, Lopardo, Gustavo, Goecke, Bernardo, Feijooó Seoane, Rosa María, Mahmood, Sayed Faisal, Khan, Ejaz Ahmed, Akram, Jayed, Abbas, Salma, Salahuddin, Naseem, Rozhkova, Elena, Zubkova, Tatyana · 2022 · The Lancet
Cited by 225

The DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.

Abstract

Background The Ad5-nCoV vaccine is a single-dose adenovirus type 5 (Ad5) vectored vaccine expressing the SARS-CoV-2 spike protein that was well-tolerated and immunogenic in phase 1 and 2 studies. In this study, we report results on the final efficacy and interim safety analyses of the phase 3 trial. Methods This double-blind, randomised, international, placebo-controlled, endpoint-case driven, phase 3, clinical trial enrolled adults aged 18 years older at study centres in Argentina, Chile, Mexico, Pakistan, and Russia. Participants were eligible for the study if they had no unstable or severe underlying medical or psychiatric conditions; had no history of a laboratory-confirmed SARS-CoV-2 infection; were not pregnant or breastfeeding; and had no previous receipt of an adenovirus-vectored, coronavirus, or SARS-CoV-2 vaccine. After informed consent was obtained, 25 mL of whole blood was withdrawn from all eligible participants who were randomised in a 1:1 ratio to receive a single intramuscular dose of 0·5 mL placebo or a 0·5 mL dose of 5 × 1010 viral particle (vp)/mL Ad5-nCoV vaccine; study staff and participants were blinded to treatment allocation. All participants were contacted weekly by email, telephone, or text message to self-report any symptoms of COVID-19 illness, and laboratory testing for SARS-CoV-2 was done for all participants with any symptoms. The primary efficacy objective evaluated Ad5-nCoV in preventing symptomatic, PCR-confirmed COVID-19 infection occurring at least 28 days after vaccination in all participants who were at least 28 days postvaccination on Jan 15, 2021. The primary safety objective evaluated the incidence of any serious adverse events or medically attended adverse events postvaccination in all participants who received a study injection. This trial is closed for enrolment and is registered with ClinicalTrials.gov (NCT04526990). Findings Study enrolment began on Sept 22, 2020, in Pakistan, Nov 6, 2020, in Mexico, Dec 2, 2020, in Russia and Chile, and Dec 17, 2020, in Argentina; 150 endpoint cases were reached on Jan 15, 2021, triggering the final primary efficacy analysis. One dose of Ad5-nCoV showed a 57·5% (95% CI 39·7–70·0, p=0·0026) efficacy against symptomatic, PCR-confirmed, COVID-19 infection at 28 days or more postvaccination (21 250 participants; 45 days median duration of follow-up [IQR 36–58]). In the primary safety analysis undertaken at the time of the efficacy analysis (36 717 participants), there was no significant difference in the incidence of serious adverse events (14 [0·1%] of 18 363 Ad5-nCoV recipients and 10 [0·1%] of 18 354 placebo recipients, p=0·54) or medically attended adverse events (442 [2·4%] of 18 363 Ad5-nCoV recipients and 411 [2·2%] of 18 354 placebo recipients, p=0·30) between the Ad5-nCoV or placebo groups, or any serious adverse events considered related to the study product (none in both Ad5-nCoV and placebo recipients). In the extended safety cohort, 1004 (63·5%) of 1582 of Ad5-nCoV recipients and 729 (46·4%) of 1572 placebo recipients reported a solicited systemic adverse event (p<0·0001), of which headache was the most common (699 [44%] of Ad5-nCoV recipients and 481 [30·6%] of placebo recipients; p<0·0001). 971 (61·3%) of 1584 Ad5-nCoV recipients and 314 (20·0%) of 1573 placebo recipients reported an injection-site adverse event (p<0·0001), of which pain at the injection site was the most frequent; reported by 939 (59%) Ad5-nCoV recipients and 303 (19%) placebo recipients. Interpretation One dose of Ad5-nCoV is efficacious and safe in healthy adults aged 18 years and older. Funding CanSino Biologics and the Beijing Institute of Biotechnology.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/s0140-6736(21)02753-7

Cites

11 of 11 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 11 references

Cited by

See all 225

Metadata

Authors
Halperin, S. A., Ye, L., MacKinnon-Cameron, D., Smith, B., Cahn, P. E., Ruiz-Palacios, G. M., Ikram, A., Lanas, F., Lourdes Guerrero, M., Muñoz Navarro, S. R., Sued, O., Lioznov, D. A., Dzutseva, V., Parveen, G., Zhu, F., Leppan, L., Langley, J. M., Barreto, L., Gou, J., Zhu, T., Mao, H., Gagnon, L., Tran, S.-P., Khan, S. T., Becerra Aquino, A. G., Saldaña Montemayor, E. E., Rivera Martínez, N. E., Bohórquez López, V. C., Simón Campos, J. A., Pineda Cárdenas, F. D. J., Chen, W., Hou, L., Zhang, Z., Corral, G., López, E., Teijeiro, R., Alzogaray, M. F., Zaidman, C., Lopardo, G., Goecke, B., Feijooó Seoane, R. M., Mahmood, S. F., Khan, E. A., Akram, J., Abbas, S., Salahuddin, N., Rozhkova, E., & Zubkova, T.
Venue
The Lancet
Publisher
Elsevier BV
Published
2022-01
Volume
399
Issue
10321
Pages
237-248
ISSN
  • 0099-5355 (ISSN-L)
  • 0140-6736
OpenAlex
W4200135346
Cited by
225
References
11
FWCI
13.40
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Final efficacy analysis, interim safety analysis, and immunogenicity of a single dose of recombinant novel coronavirus vaccine (adenovirus type 5 vector) in adults 18 years and older: an international, multicentre, randomised, double-blinded, placebo-controlled phase 3 trial. https://app.cochat.ai/papers/10.1016/s0140-6736(21)02753-7
The paper
Halperin, S. A., Ye, L., MacKinnon-Cameron, D., Smith, B., Cahn, P. E., Ruiz-Palacios, G. M., Ikram, A., Lanas, F., Lourdes Guerrero, M., Muñoz Navarro, S. R., Sued, O., Lioznov, D. A., Dzutseva, V., Parveen, G., Zhu, F., Leppan, L., Langley, J. M., Barreto, L., Gou, J., . . . Zubkova, T. (2022). Final efficacy analysis, interim safety analysis, and immunogenicity of a single dose of recombinant novel coronavirus vaccine (adenovirus type 5 vector) in adults 18 years and older: an international, multicentre, randomised, double-blinded, placebo-controlled phase 3 trial. The Lancet. https://doi.org/10.1016/s0140-6736(21)02753-7

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.